Clozex Medical Inc
$170.2K 6 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. reported $170,171.73 across General Payments, Research, and Ownership to 869 physicians and teaching hospitals across 869 transactions.
- $170.2K Below-median payer
- All-tracks total
- 869 Above-median volume
- Transactions
- 869 Above-median reach
- Recipients
- −$116.0K
- General Payments vs PY2023
Alcresta Therapeutics, Inc. reported $170,171.73 across all CMS Open Payments tracks (General + Research + Ownership) to 869 physicians and teaching hospitals in Program Year 2024 - ranking #1048 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $170,171.73, averaging $195.82 per recipient.
Alcresta Therapeutics, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
21/100
Total payments
F
12/100
Transaction volume
F
16/100
Physician reach
F
17/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer alcresta-therapeutics-inc Alcresta Therapeutics, Inc.
$170.2K · #1048/1,925 · 0.0% industry · PY2024
- TOT $170.2K
- RANK #1048
- SHARE 0.0%
- TXN 869
- RCP 869
- CAT 3
- GEN $170.2K
- ΔGEN −$116.0K
- TOP1 24.5%
- PY 2024
Volume peers
Nearest volume peer: Clozex Medical Inc ($170.2K)
Alcresta Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Alcresta Therapeutics, Inc.'s CMS-reported General Payments decreased by $116.0K (−40.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ALCRESTA THERAPEUTICS, INC.PY2023: ALCRESTA THERAPEUTICS, INC.PY2024: Alcresta Therapeutics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $286,203.06
- PY2024
- $170,171.73
What the Data Shows for Alcresta Therapeutics, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Alcresta Therapeutics, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 3 general-payment categories charted below, "Honoraria" is the largest at $126.2K across 50 transactions, 74.2% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Honoraria" leads Alcresta Therapeutics, Inc.'s 3-category general-payment breakdown at $126.2K, 74.2% of the reported total.
How Alcresta Therapeutics, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $126.2K | 50 | 74.2% |
| Food and Beverage | $33.9K | 766 | 19.9% |
| Travel and Lodging | $10.1K | 53 | 5.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $113,352.07 (66.6%) of $170,171.73 in this company's General Payments records across 556 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Alcresta Therapeutics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Valeria Cohran
$41,743.08 across 48 reported transactions
- 2
Candi Jump
$23,944.58 across 25 reported transactions
- 3
Stephanie Abrams
$23,158.38 across 20 reported transactions
- 4
Akash Pandey
$15,034.27 across 13 reported transactions
- 5
Mary Garcia
$9,471.76 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Alcresta Therapeutics, Inc.'s spend rank (#1048 of 1,925, bottom 46% by spend) and concentration rank (#970 of 1,838, bottom 47% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Kamada Ltd. : $83.4K total payments, HHI 1166
- Pulpdent Corporation : $80.0K total payments, HHI 1162
- Optos, Inc. : $585.3K total payments, HHI 1153
- HemoSonics LLC : $100.7K total payments, HHI 1152
- Intercept Pharmaceuticals, Inc. : $2.8M total payments, HHI 1149
- Asensus Surgical, Inc. : $207.1K total payments, HHI 1147
- Alcresta Therapeutics, Inc. (this company) : $170.2K total payments, HHI 1141
- Pathway Medical Partners, LLC : $66.0K total payments, HHI 1140
- Visionix USA, Inc : $108.9K total payments, HHI 1138
- Anika Therapeutics, Inc. : $1.1M total payments, HHI 1135
- Woven Orthopedic Technologies, LLC : $1.2K total payments, HHI 1134
- MY01 Inc. : $29.5K total payments, HHI 1134
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Alcresta Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Alcresta Therapeutics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Alcresta Therapeutics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Draeger Medical Systems, Inc
$169.2K 95 recipients
Compare payment profiles
Quanta Dialysis Technologies Inc
$169.2K 2 recipients
Compare payment profiles
Hexal AG
$168.9K 19 recipients
Compare payment profiles
Carl Zeiss Meditec Digital Innovations LLC
$167.7K 34 recipients
Compare payment profiles
Bioprotect Medical, Inc.
$165.6K 954 recipients
Compare payment profiles
Put this to use
Alcresta Therapeutics, Inc. ranks #1048 of 1,925 by all-tracks total payments, led by "Honoraria".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Alcresta Therapeutics, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.